From Annals of Neurologie
Vol. 89
Issue 2
Feb.21
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ana.26028?download=true
Jetzt muß ich mich um diese Uhrzeit noch durch einen englischen Text kämpfen???
Das was ich beim Querlesen verstanden hab hat Marc schon vor Monaten geschrieben und Prof. Rieckmann bei einer DMSG-Veranstaltung gesagt…
Und nu???
Nighty
“Muss”? Keinesfalls. Kämpfen? Sorry, ich muss mit Deutsch kämpfen 
Im März 2020? Nö, unmöglich. Die haben doch Zeit gebraucht, um unterschiedliche Verläufe zu beobachten.
Es handelt sich nicht um das Infektionsrisiko, sondern um severety, Verlauf/Folgen vom Covid.
Für mich war interessant insb. SS. 12 und 13,wo es um Intf. und Ocrelizumab handelte.
Auch habe ich nicht gewusst, dass in Italien DMF am häufigsten eingesetzt wird (nebenbei).
We did not observe a link between time to last infusion of Ocrelizumab and Covid-19 risk. This preliminary result needs to be confirmed, but it is consistent with the idea that the immunological effects of Ocrelizumab may last longer than 6 months.
“We did not observe a link between time to last infusion of Ocrelizumab and Covid-19 risk. This preliminary result needs to be confirmed, but it is consistent with the idea that the immunological effects of Ocrelizumab may last longer than 6 months.”
The role of Interferon treatment and the severity of Covid-19 is of high interest. Our data indicated a decrease of risk associated to Interferon, even if it did not reach the statistical significance. The majority of laboratory studies are in line with this preliminary observation, suggesting that supplementing type I interferons may circumvent a defective response that, in people with severe Covid-19, may depend on various mechanisms including: the presence of anti-interferon auto- antibodies,27 a genetically defective type I interferon response,28, 29 or the ability of SARS-CoV-2 to neutralize the antiviral effects of type I interferons.30 A recent clinical trial of interferon beta-1b and lopinavir-ritonavir in Middle East Respiratory Syndrome31 supports this hypothesis but a negative trial of interferon beta-1b, alone or in combination with lopinavir, does not.32 It is possible that timing in the administration of type I interferons is crucial as early therapy is associated with favorable clinical responses.33 This is in accord with our observation in patients who are already under interferon beta therapy whey they develop Covid-19."